HSR22-156: Patient Perspectives on Progression-Free Survival and Quality of Life in Metastatic Breast Cancer

View More View Less
  • 1 Metastatic Breast Cancer Network, New York, NY
  • | 2 SHARE Cancer Support, New York, NY
  • | 3 European Cancer Patient Coalition, Brussels, Belgium
  • | 4 PRECISIONheor, Los Angeles, CA
  • | 5 Sanofi Genzyme, Bridgewater, NJ
  • | 6 Champalimaud Clinical Center, Lisbon, Portugal
  • | 7 ABC Global Foundation, Lisbon, Portugal

INTRODUCTION: Advances in treatment for metastatic breast cancer (mBC) have improved overall survival in some mBC subtypes. However, there is still no cure for mBC and navigating cancer treatment remains daunting for patients due to treatment toxicities and impacts to quality of life (QoL). Considering the use of progression-free survival (PFS) and other endpoints in clinical trials, it is important to understand the value patients place on clinical concepts used to assess treatment efficacy. This study explored global patient perceptions of and experiences with the concept of progression-free survival (PFS) and its relation, if any, to QoL. Materials and Methods: We convened virtual roundtables in Europe and the United States and conducted virtual interviews in Japan with mBC patients, patient advocates, and thought leaders. Participants were asked about clinical endpoints such as PFS and how these relate to QoL and treatment decision-making. Transcripts from the roundtables and interviews were analyzed using thematic analysis. Results: Overall survival benefit combined with good QoL remain the most important endpoints for patients with mBC, with participants noting that QoL is a dynamic concept that varies throughout the treatment journey. Living longer is a priority, and the time when disease is not progressing can also be meaningful to patients when coupled with improvements in QoL and no added treatment toxicity. However, participants noted that the concept of PFS is not well understood by patients, underscoring the need for more patient-friendly terminology. Participants identified facets of care that patients with mBC value and that may be related to periods of time without disease progression, including relief from disease impacts and treatment-related side effects. Participants highlighted the need for improved communication between patients and their physicians to align on treatment priorities, manage treatment-related toxicities and address psychosocial challenges to maintain desired QoL. Conclusion: While overall survival is considered the most important endpoint to their goal of living longer, patients also value periods of time without disease progression, as long as QoL during this time period is not adversely impacted. There remains an unmet need for more patient-centered clinical terminology to illustrate the concept of PFS, more holistic care throughout the treatment journey, and a greater focus on the dynamic construct of QoL.

Corresponding Author: Suepattra G. May, PhD, MPH